Blog
RSS FeedPosted by Michael Wonder on 28 Sep 2023
The use of historical controls in clinical trials
28 September 2023 - A randomised clinical trial is frequently the preferred research design for testing new medical treatments. Randomisation helps ...
Posted by Michael Wonder on 26 Jun 2023
New report from The King’s Fund shows the UK underperforming on treatable health conditions, says the ABPI
26 June 2023 - The King’s Fund today published their independent report commissioned by the ABPI comparing the NHS to other ...
Posted by Michael Wonder on 31 Jan 2023
International price comparison of medicines (2022)
31 January 2023 - The price of prescription drugs in Sweden has fallen compared to other countries since 2014 and is ...
Posted by Michael Wonder on 02 Jan 2023
Korea to exclude Australia from new drug pricing reference country list
30 December 2022 - HIRA has decided to leave Australia as a reference country when it sets drug prices next ...
Posted by Michael Wonder on 24 Nov 2022
Korea to add Canada, Australia to drug pricing reference country list
24 November 2022 - The Government said it would additionally reference Canada and Australia when setting drug prices from January ...
Posted by Michael Wonder on 25 Jul 2022
U.S. drug prices sky high in international comparison
22 July 2022 - U.S. residents are paying more than twice as much for prescription drugs as people living in other ...
Posted by Michael Wonder on 11 Sep 2021
Estimated savings from international reference pricing for prescription drugs
10 September 2021 - High prescription drug prices have important implications for health care spending, patient financial burden, and adherence. ...
Posted by Michael Wonder on 05 Aug 2021
U.S. health care system ranks last among 11 high income countries, researchers say
5 August 2021 - The United States has the worst health care system overall among 11 high income countries, even ...
Posted by Michael Wonder on 01 Jul 2021
Analysis of launch and post-approval cancer drug pricing, clinical benefit, and policy implications in the US and Europe
1 June 2021 - In this economic evaluation of the US compared with 3 European countries, launch prices of cancer drugs ...
Posted by Michael Wonder on 31 May 2021
State slower to ‘adopt new drugs’ than most of western Europe
31 May 2021 - Medicines regularly not worth approving at asking price. ...
Posted by Michael Wonder on 31 May 2021
External reference pricing: the drug pricing reform America needs?
27 May 2021 - External reference pricing, sometimes known as international reference pricing, refers to the practice of informing price negotiations ...
Posted by Michael Wonder on 30 Apr 2021
Americans paid two to four times as much for some drugs as in three other countries
28 April 2021 - Amid national angst over the cost of prescription drugs, a new analysis finds that U.S. consumers ...
Posted by Michael Wonder on 12 Apr 2021
International reference pricing for prescription drugs in the United States: administrative limitations and collateral effects
12 April 2021 - Many countries use international (or external) reference pricing—benchmarking prices against those in other countries—to manage spending ...
Posted by Michael Wonder on 03 Nov 2020
Regulatory policy may not stop comparative efficacy trials
4 November 2020 - The way Sarfaraz K. Niazi, looks at it, doing comparative efficacy studies in humans to confirm that ...
Posted by Michael Wonder on 08 Oct 2020
Association between FDA and EMA expedited approval programs and therapeutic value of new medicines: retrospective cohort study
7 October 2020 - The investigators of the study set out to characterise the therapeutic value of new drugs approved ...